X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company plans to use the raised capital, grants, and awards to complete its preclinical studies for Lactiga’s two primary development programs, LCTG-001 (for patients with Common Variable Immunodeficiency) and LCTG-002 (for patients with COVID-19 and its variants).
Lead Product(s): LCTG-001
Therapeutic Area: Immunology Product Name: LCTG-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: 1517 Fund
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Financing September 21, 2022
Details:
Lactiga entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. Partners secured an NIH R01 Emergency Award of over $2MM to advance this study.
Lead Product(s): LCTG-001
Therapeutic Area: Infections and Infectious Diseases Product Name: LCTG-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
